Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily activities by up to 13 months, though their clinical relevance remains debated.
FDA Approves First Novel Drug for Schizophrenia in Decades
The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of drug for the condition in more
September 28, 2024